Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination

Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination GlobeNewswire July 11, 2025 Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025 SOUTH SAN FRANCISCO & BOSTON, July 11, 2025 (GLOBE NEWSWIRE) — Helix Acquisition Corp. II (“Helix“) (Nasdaq: HLXB), a special purpose acquisition company […]

Strengthening UK Ties: ComplyControl Becomes Associate Member of UK Finance

ComplyControl, a provider of cutting-edge AI-driven solutions for banks and financial institutions, is excited to announce that it has officially become an Associate Member of UK Finance, the leading trade association for the UK financial services sector. https://mma.prnewswire.com/media/2729421/ComplyControl_x_UK_Finance.jpg ComplyControl made its entry into the UK market in 2024, with a clear mission of making regulatory

Alchemy Pay Accelerates Regulatory Expansion in the U.S. with South Carolina MTL License Approval

Alchemy Pay, the world-leading fiat-crypto payment gateway, today announced that it has been granted a Money Transmitter License (MTL) in the state of South Carolina, marking a significant addition to its growing portfolio of regulatory approvals in the United States. https://mma.prnewswire.com/media/2155297/image_5017751_41593380_Logo.jpg With the inclusion of South Carolina, Alchemy Pay now holds MTLs in ten U.S.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Cable One, Inc. (CABO)

NEW YORK, NY / ACCESS Newswire / July 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cable One, Inc. ("Cable One, Inc.") (NYSE:CABO) concerning possible violations of federal securities laws. On May 2, 2025, Cable One missed earnings expectations by nearly $8 and suspended its dividend. Analysts at

Shareholders of 3D Systems Corporation (DDD): Protect Your Rights Before August 12, 2025 – Contact Levi & Korsinsky

NEW YORK, NY / ACCESS Newswire / July 11, 2025 / If you suffered a loss on your 3D Systems Corporation (NYSE:DDD) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/3d-systems-corporation-lawsuit-submission-form?prid=156338&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

Viewbix: Metagramm Unveils AI-Powered Grammar Solution for Enterprises Seeking Secure, Private, and Customized Language Models

(NASDAQ:VBIX), New on-premises grammar engine to revolutionize enterprise language accuracy using proprietary data Tel Aviv, Israel, July 11, 2025 (GLOBE NEWSWIRE) — Viewbix Inc. (Nasdaq: VBIX) (“Viewbix” or the “Company”), a global developer of ad-tech innovative technologies, today announces that Metagramm Software Ltd. (“Metagramm”), a leading innovator in enterprise AI solutions and its wholly-owned subsidiary,

Exhale Wellness Ranked No.1 THCA Flower Brand in 2025

Charlotte, NC, July 11, 2025 (GLOBE NEWSWIRE) — Exhale Wellness has been officially recognized as the No. 1 THCA flower brand in 2025 by top industry peers. The recognition is based on the company's consistent focus on product quality, verified lab testing, and compliance with legal and safety standards. Reviewers highlighted Exhale's transparency in sourcing,

MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer

(NASDAQ:INKT), NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the publication of another landmark case in Nature's Oncogene describing a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer, following treatment

BriaCell’s Bria-IMT(TM) Demonstrates Survival Advantage over Trodelvy(R) and Control Group in Metastatic Breast Cancer

(TSX:BCT),(NASDAQ:BCTX),(NASDAQ:BCTXW),(NASDAQ:BCTXZ), Median Overall Survival (OS) of 13.9 months in triple negative breast cancer (TNBC) exceeds Trodelvy (11.8 months) and doubles control (6.9 months) OS of 17.3 months in HR+ metastatic breast cancer surpasses Trodelvy (14.4 months) and control (11.2 months) No treatment related discontinuations reported PHILADELPHIA and VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE)

Zevra Therapeutics Announces MIPLYFFA(R) (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference

(NASDAQ:ZVRA), CELEBRATION, Fla., July 11, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an oral presentation and two poster presentations on MIPLYFFA(R) (MY-PLY-FAH) (arimoclomol) are being featured at the National Niemann Pick Disease Foundation (NNPDF)

Scroll to Top